Takuya Oikawa
Overview
Explore the profile of Takuya Oikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ujiie H, Nishiya N, Yamamoto A, Takada T, Onodera M, Sasaki A, et al.
Cancer Chemother Pharmacol
. 2024 Aug;
94(4):561-569.
PMID: 39141082
Purpose: Hair cell damage is a common side effect caused by the anticancer drug cisplatin (CDDP), which reduces patient quality of life. One CDDP resistance mechanism that occurs in recurrent...
2.
Sato M, Sakata Y, Sato K, Nochioka K, Miura M, Abe R, et al.
Int J Cardiol Heart Vasc
. 2020 Mar;
27:100497.
PMID: 32215317
Background: Since most of the randomized clinical trials for heart failure (HF) were designed to exclude elderly patients, limited data are available on their clinical characteristics, prognosis, and prognostic factors....
3.
Oikawa T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, et al.
Int J Cardiol
. 2019 Jul;
293:17-24.
PMID: 31358306
Background: Several studies have reported that C-reactive protein (CRP), an inflammatory biomarker, predicts cardiovascular events independently of low-density lipoprotein cholesterol levels. However, no study examined whether temporal changes in CRP...
4.
Oikawa T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, et al.
Int J Cardiol
. 2019 May;
290:106-112.
PMID: 31104823
Background: Although several factors, including heart failure (HF) and inflammation, are known to increase the incidence of cancer, it remains unknown whether HF may increase cancer mortality, especially with a...
5.
Suzuki K, Oikawa T, Nochioka K, Miura M, Kasahara S, Sato M, et al.
Arterioscler Thromb Vasc Biol
. 2019 Mar;
39(5):934-944.
PMID: 30866657
Objective- Secondary prevention for recurrent myocardial infarction (MI) is one of the most important therapeutic goals in patients with old MI (OMI). Although statins are widely used for this purpose,...
6.
Abe R, Sakata Y, Nochioka K, Miura M, Oikawa T, Kasahara S, et al.
J Cardiol
. 2019 Jan;
73(5):370-378.
PMID: 30606681
Background: Self-care behaviors (ScB) are associated with symptoms and outcomes in patients with heart failure (HF). However, little is known about gender differences in the prognostic relevance of ScB in...
7.
Kasahara S, Sakata Y, Nochioka K, Tay W, Claggett B, Abe R, et al.
Int J Cardiol
. 2018 Nov;
284:42-49.
PMID: 30413304
Background: Few simple risk models, without echocardiography have been developed for patients with heart failure (HF) and preserved left ventricular ejection fraction (LVEF) (HFpEF). Methods: To develop a risk score...
8.
Hao K, Takahashi J, Sakata Y, Miyata S, Shiroto T, Nochioka K, et al.
Int J Cardiol
. 2018 Oct;
278:22-27.
PMID: 30366856
Background: Complete revascularization with PCI is not always achieved in patients with ischemic HF. Therefore, this study aimed to elucidate the prognostic impact of residual coronary stenosis (RS) after percutaneous...
9.
Kasahara S, Sakata Y, Nochioka K, Yamauchi T, Onose T, Tsuji K, et al.
Heart Vessels
. 2018 Mar;
33(9):997-1007.
PMID: 29569034
We aimed to compare the usefulness of plasma levels of B-type natriuretic peptide (BNP) for long-term risk stratification among patients with heart failure (HF) with preserved left ventricular ejection fraction...
10.
Oikawa T, Sakata Y, Nochioka K, Miura M, Tsuji K, Onose T, et al.
J Am Heart Assoc
. 2018 Mar;
7(6).
PMID: 29540427
Background: The beneficial prognostic impact of statins has been established in patients with ischemic heart disease but not in those with heart failure (HF). In addition, it is still unclear...